So that 3rd to last line - ‘The data in the abstract must not be published prior to the SITC 38th Annual Meeting.’ With that inclusion, are we to assume that if whatever it is IMU is presenting meets the criteria above for late-breaking abstract, even if they wanted to they were not able to publish data prior to SITC? Is that how you interpret it?
Ann: Imugene Phase 1 onCARlytics CD19 virus clinical trial opens, page-135
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
-0.003(6.82%) |
Mkt cap ! $304.9M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.4¢ | 4.1¢ | $1.607M | 38.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 4542680 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.3¢ | 1675759 | 9 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |